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Bleeding reduction in cardiac surgery: A
combined approach
To the Editor:
We read with interest the article by Hayashida and
colleagues1 concerning the effects of minimal-dose apro-
tinin on coronary bypass. Looking for new strategies to
reduce bleeding during heart surgery, we have conducted
a prospective, randomized, double-blind trial of topical
aprotinin versus placebo in 100 patients undergoing car-
diac operations with systemic aprotinin in the pump
prime.
Fifty patients received topical aprotinin plus systemic
aprotinin (group A), and 50 patients received only sys-
temic aprotinin and placebo into the pericardial cavity
(group B). All the patients underwent coronary artery
bypass grafting. The trial started in January 1997 and
ended in December 1997. Aprotinin (50 ml; 500,000 KIU)
in group A or placebo (50 ml) in group B was applied
topically to the heart, pericardium, and mediastinal struc-
tures for 5 minutes before sternal closure. All patients had
general aprotinin in the pump prime (100 ml; 1,000,000
KIU). The same surgeon (F.B.) was involved in all cardiac
operations. The groups were homogeneous for extracor-
poreal circulation time, number of anastomoses, and
hemocoagulative parameters. Four patients required re-
entry for bleeding, with a surgical site identified in only
one patient in group B. These patients were eliminated
from analysis of the difference in blood loss. Mean blood
loss was significantly less in the topical aprotinin group
(247 vs 427 ml; p 5 0.001), and fewer patients required
transfusions (7 vs 14, respectively).
In accordance with the experience of the Oxford
group,2 we tried to reduce bleeding by using aprotinin
molecules acting from “inside” and historically from “out-
side.” Much more information we need about the long-
term effects and influence on pericardial and mediastinal
structures,3 but these preliminary results show that the
addition of aprotinin to the extracorporeal circuit and
topical application should reduce the need for blood
products, reducing the risks to the patient and the costs to
the health service.
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